GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Adaptive Biotechnologies Corp (NAS:ADPT) » Definitions » Purchase Of Business

Adaptive Biotechnologies (Adaptive Biotechnologies) Purchase Of Business

: $0.0 Mil (TTM As of Dec. 2023)
View and export this data going back to 2019. Start your Free Trial

Adaptive Biotechnologies's purchase of business for the three months ended in Dec. 2023 was $0.0 Mil. It means Adaptive Biotechnologies spent $0.0 Mil on purchasing business. Adaptive Biotechnologies's purchase of business for the trailing twelve months (TTM) ended in Dec. 2023 was $0.0 Mil.

Compared with last quarter ($0.0 Mil in Sep. 2023 ), Adaptive Biotechnologies spent the same money on purchasing business in Dec. 2023 ($0.0 Mil).


Adaptive Biotechnologies Purchase Of Business Historical Data

The historical data trend for Adaptive Biotechnologies's Purchase Of Business can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Adaptive Biotechnologies Annual Data
Trend Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Purchase Of Business
Premium Member Only Premium Member Only - - - - -

Adaptive Biotechnologies Quarterly Data
Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23
Purchase Of Business Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

Adaptive Biotechnologies Purchase Of Business Calculation

The amount used to purchase business.

Purchase Of Business for the trailing twelve months (TTM) ended in Dec. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was $0.0 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Adaptive Biotechnologies Purchase Of Business Related Terms

Thank you for viewing the detailed overview of Adaptive Biotechnologies's Purchase Of Business provided by GuruFocus.com. Please click on the following links to see related term pages.


Adaptive Biotechnologies (Adaptive Biotechnologies) Business Description

Traded in Other Exchanges
Address
1165 Eastlake Avenue East, Seattle, WA, USA, 98109
Adaptive Biotechnologies Corp is a company advancing the field of immune-driven medicine by harnessing the inherent biology of the adaptive immune system to transform the diagnosis and treatment of disease. Its clinical diagnostic product, clonoSEQ, is test authorized by the FDA for the detection and monitoring of minimal residual disease ("MRD") in patients with multiple myeloma ("MM"), B cell acute lymphoblastic leukemia ("ALL") and chronic lymphocytic leukemia ("CLL") and is also available as a CLIA-validated laboratory developed test ("LDT") for patients with other lymphoid cancers, including diffuse large B-cell lymphoma ("DLBCL").
Executives
Kyle Piskel officer: Principal Accounting Officer C/O ADAPTIVE BIOTECHNOLOGIES CORPORATION, 1551 EASTLAKE AVE E STE 200, SEATTLE WA 98102
Nitin Sood officer: Chief Commercial Officer, MRD C/O ADAPTIVE BIOTECHNOLOGIES CORPORATION, 1551 EASTLAKE AVE E STE 200, SEATTLE WA 98102
Tycho Peterson officer: Chief Financial Officer C/O ADAPTIVE BIOTECHNOLOGIES CORPORATION, 1165 EASTLAKE AVE E, SEATTLE WA 98109
R Mark Adams officer: Chief Operating Officer C/O ADAPTIVE BIOTECHNOLOGIES CORPORATION, 1551 EASTLAKE AVE E STE 200, SEATTLE WA 98102
Michelle Renee Griffin director 19723 NE 65TH LANE, KIRKLAND WA 98033
Stacy L Taylor officer: SVP and General Counsel C/O ADAPTIVE BIOTECHNOLOGIES CORPORATION, 1551 EASTLAKE AVENUE E SUITE 200, SEATTLE WA 98102
Leslie Trigg director C/O OUTSET MEDICAL, 1830 BERING ROAD, SAN JOSE CA 95112
Kevin T Conroy director 5505 ENDEAVOR LANE, MADISON WI 53719
Robert Hershberg director 3005 FIRST AVENUE, SEATTLE WA 98121
Peter M Neupert director 13920 SE EASTGATE WAY, STE 300, BELLEVUE WA 98005
Sharon Benzeno officer: Chief Commercial Ofc Imm Med C/O ADAPTIVE BIOTECHNOLOGIES CORPORATION, 1551 EASTLAKE AVE E STE 200, SEATTLE WA 98102
Harlan S Robins officer: Chief Scientific Officer C/O ADAPTIVE BIOTECHNOLOGIES CORPORATION, 1551 EASTLAKE AVE E STE 200, SEATTLE WA 98102
Francis Lo officer: Chief People Officer C/O ADAPTIVE BIOTECHNOLOGIES CORPORATION, 1551 EASTLAKE AVE E STE 200, SEATTLE WA 98102
Michael J Pellini director 222 DUTTON MILL RD, WILLISTOWN PA 19380
Chad M Robins director, officer: CEO and Chairman C/O ADAPTIVE BIOTECHNOLOGIES CORPORATION, 1551 EASTLAKE AVE E STE 200, SEATTLE WA 98102

Adaptive Biotechnologies (Adaptive Biotechnologies) Headlines

From GuruFocus